Wednesday, July 15, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

Guns now the leading cause of death for US children, CDC says

Firearms were the leading cause of death for U.S. children and adolescents for the first time in 2020, the most recent year with data available.

While studies in 2016 found that motor vehicle accidents surpassed gun deaths for children, a roughly 30% spike in the latter between 2019 and 2020 made firearms the leading cause of death, according to an analysis of CDC data published in the New England Journal of Medicine in late April.

The CDC reported 4,368 child deaths by gunfire in 2020, the vast majority of which were homicides, followed by suicides. Unintentional gun deaths and deaths where a motive could not be determined accounted for a very small portion of the data.

Source: Fox News

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!